Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clofarabine incorporated into a 5-drug regimen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Clofarabine | EXPERIMENTAL | Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion. |
| Name | Type | Description |
|---|---|---|
| Clofarabine incorporated into a 5-drug regimen | DRUG | Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine |
Inclusion Criteria: * Be in first relapse with \>25% blasts in the bone marrow with a duration of first remission of ≥6 months and no longer in the intensive phase(s) of initial ALL therapy (e.g., patients who are in the maintenance or continuation phases of therapy \[or beyond\] and who have compl...